Jinhua Qinggan Granules eShow Global
Jinhua Qinggan Granules


Juxiechang (Beijing) Pharmaceutical Co., Ltd.

China    City:Beijing

Contact information
Visible after login
Product Promotion Page
Product Details






Jinhua Qinggan Granules can strengthen immune system, relieve common cold/flu symptoms: fever, fatigue, muscle aches & painsnasal congestion, cough due to minor throat & bronchial irritation, sore throat, headache.

20201月,对102例轻型和普通型新冠肺炎患者金花清感颗粒临床对照研究,结果显示:金花清感颗粒组较西医组治疗,转重症率明显下降 (11.8% VS 29.4%);退热时间缩短(1.5天 VS 3);淋巴细胞复常率提高 (74.5% VS 64.7%)。结果表明金花清感颗粒治疗轻症和普通型具有确切的疗效。【1】

In January 2020, clinical controlled study of 102 patients with mild and common Coronavirus disease (COVID-19) showed that the Jinhua Qinggan Granules group compared with other medicine group had a significantly lower rate of becoming severe (11.8% VS 29.4%) ; the antipyretic time was shortened (1.5 days VS 3 days); lymphocyte recovery rate increased (74.5% vs 64.7%). The results show that Jinhua Qinggan Granules have proven effects on mild and common COVID-19 patients.【1】


In a comparative randomized controlled non-blind test conducted in 2010, Jinhua Qinggan Granules proved that when used on H1N1 influenza patients, it can rapidly reduce and shorten fever(Continuous fever time: 16 hrs in Jinhua Qinggan Granules  group, 20 hrs in oseltamivir group, 26 hrs in controlled group, 15 hrs in Jinhua Qinggan Granules and oseltamivir combined group), reduce antibiotic use (antibiotic use was 34.3% in the controlled group, 15.7% in oseltamivir group, 9.7% in Jinhua Qinggan Granules group, 7.8% in Jinhua Qinggan Granules and oseltamivir combined group),  and effectively relieve of symptoms. 【2】



【1】张伯礼院士:治疗新冠肺炎中西医各有所长. (2020, March 6). Retrieved March 8, 2020, from http://www.satcm.gov.cn/xinxifabu/meitibaodao/2020-03-06/13663.html

【2】Wang, C. & Cao, Bin & Liu, Q. & Zou, Z. & Liang, ZA & Gu, L. & Dong, J.. (2012). Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza. A randomized trial. (vol 155, pg 217, 2011). Annals of internal medicine. 156. 71-71. 10.1059/0003-4819-156-1-201201030-00031.